KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

PURPOSE: VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non–small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced NSCLC, but the effects have been modest. Although VEGFR2/KDR...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Nilsson, Monique B., Giri, Uma, Gudikote, Jayanthi, Tang, Ximing, Lu, Wei, Tran, Hai, Fan, Youhong, Koo, Andrew, Diao, Lixia, Tong, Pan, Wang, Jing, Herbst, Roy, Johnson, Bruce E., Ryan, Andy, Webster, Alan, Rowe, Philip, Wistuba, Ignacio I., Heymach, John V.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4834253/
https://ncbi.nlm.nih.gov/pubmed/26578684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1994
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares